CSPC Pharmaceutical Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
CSPC Pharmaceutical Group heeft een totaal eigen vermogen van CN¥36.5B en een totale schuld van CN¥388.9M, wat de schuld-eigenvermogensverhouding op 1.1% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥47.9B en CN¥11.4B. De EBIT CSPC Pharmaceutical Group is CN¥6.4B waardoor de rentedekking -29.4 is. Het heeft contanten en kortetermijnbeleggingen van CN¥10.8B.
Belangrijke informatie
1.1%
Verhouding schuld/eigen vermogen
CN¥388.87m
Schuld
Rente dekkingsratio | -29.4x |
Contant | CN¥10.82b |
Aandelen | CN¥36.47b |
Totaal verplichtingen | CN¥11.42b |
Totaal activa | CN¥47.90b |
Recente financiële gezondheidsupdates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20Recent updates
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( CN¥26.5B ) 1093 } overtreffen de korte termijn passiva ( CN¥10.4B ).
Langlopende schulden: De kortetermijnactiva 1093 ( CN¥26.5B ) overtreffen de langetermijnschulden ( CN¥988.7M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 1093 heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van 1093 is de afgelopen 5 jaar gestegen van 0.3% naar 1.1%.
Schuldendekking: De schuld van 1093 wordt goed gedekt door de operationele kasstroom ( 1101.6% ).
Rentedekking: 1093 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.